Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 927Neoplasms 612Breast Neoplasms 611Colorectal Neoplasms 458Neoplasm Metastasis 398Ovarian Neoplasms 333Prostatic Neoplasms 316Melanoma 316Lung Neoplasms 294Multiple Myeloma 293Recurrence 281Squamous Cell Carcinoma of Head and Neck 248Stomach Neoplasms 232Pancreatic Neoplasms 231Leukemia, Myeloid, Acute 224Triple Negative Breast Neoplasms 193Endometrial Neoplasms 190Carcinoma, Renal Cell 183Lymphoma, Non-Hodgkin 178Carcinoma, Hepatocellular 178Small Cell Lung Carcinoma 166Leukemia, Lymphocytic, Chronic, B-Cell 158Advanced Solid Tumors 158Lymphoma, Follicular 150Lymphoma, Large B-Cell, Diffuse 141Urinary Bladder Neoplasms 140Lymphoma 138Advanced Solid Tumor 137Uterine Cervical Neoplasms 136Head and Neck Neoplasms 134

Interventions

tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hepatic Impairment × 1 year × Clear all
NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Ipsen

Phase 1 Terminated
18 enrolled
Other solid neoplasm

Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡